Hologic, Inc. $HOLX is Sound Shore Management Inc CT’s 9th Largest Position

Sound Shore Management Inc CT cut its stake in Hologic, Inc. (NASDAQ:HOLX) by 3.3% in the third quarter, HoldingsChannel reports. The fund owned 1,337,653 shares of the medical equipment provider’s stock after selling 45,037 shares during the period. Hologic accounts for approximately 3.0% of Sound Shore Management Inc CT’s investment portfolio, making the stock its 9th largest holding. Sound Shore Management Inc CT’s holdings in Hologic were worth $90,278,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Hologic by 10.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock valued at $2,395,000 after purchasing an additional 3,520 shares in the last quarter. Empowered Funds LLC grew its position in Hologic by 27.7% during the first quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock valued at $1,081,000 after buying an additional 3,790 shares during the period. Aberdeen Group plc increased its holdings in Hologic by 2.8% in the second quarter. Aberdeen Group plc now owns 244,997 shares of the medical equipment provider’s stock valued at $15,964,000 after buying an additional 6,589 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its position in shares of Hologic by 82.8% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 30,917 shares of the medical equipment provider’s stock worth $2,015,000 after acquiring an additional 14,002 shares during the period. Finally, MGO One Seven LLC boosted its stake in shares of Hologic by 8.1% during the 2nd quarter. MGO One Seven LLC now owns 3,730 shares of the medical equipment provider’s stock worth $243,000 after acquiring an additional 278 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Down 0.1%

HOLX stock opened at $75.09 on Thursday. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. The firm has a 50-day moving average of $74.89 and a two-hundred day moving average of $71.46. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $75.36. The company has a market cap of $16.76 billion, a price-to-earnings ratio of 31.29, a PEG ratio of 2.24 and a beta of 0.72.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The company had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter last year, the company earned $0.87 earnings per share. Hologic’s revenue for the quarter was up 2.5% on a year-over-year basis. As a group, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on HOLX shares. BNP Paribas Exane lowered Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target for the company. in a research note on Friday, November 21st. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $78.00 price objective on shares of Hologic in a report on Wednesday, October 22nd. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Stephens downgraded Hologic from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $78.00 to $76.00 in a research note on Wednesday, October 22nd. Finally, Mizuho cut shares of Hologic from an “outperform” rating to a “neutral” rating and lifted their price target for the company from $70.00 to $78.00 in a research note on Thursday, October 23rd. Two equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat, Hologic presently has a consensus rating of “Hold” and an average target price of $78.42.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.